Jump to content

Property:Comorbidity

From CAMIH

This is a property of type Text.

Showing 20 pages using this property.
B
C
Past smokers n (%): Carnitin + Sildenafil 16 (55.1), Sildenafil + Placebo 18 (56.2), Placebo 18 (56.1); Compensated hypertension n (%): Carnitin + Sildenafil 18 (62.7), Sildenafil + Placebo 19 (53.1), Placebo 19 (54.2); Hypercholesterolemia n (%): Carnitin + Sildenafil 16 (55.1), Sildenafil + Placebo 17 (53.1), Placebo 17 (48.6); Obesity n (%): Carnitin + Sildenafil 3 (10.3), Sildenafil + Placebo, 3 (9.3), Placebo 4 (6.7)  +
Carnitine deficiency; carnitine deficiency was defined as free carnitine less than 35 µmol/L for males or less than 25 µmol/L for females (normal range 35-67 and 25-55, respectively), or an acyl-carnitine ratio of more than 0.4 (acylcarnitine ratio 0.4 total acyl-carnitine - free acyl-carnitine/free acyl-carnitine)  +
Carnitine deficiency (free carnitine < 35 µmol/L for men or < 25 µmol/L for women or acyl/free carnitine ratio > 0.4; Baseline: intervention arm: 34% and placebo arm: 32%) Medication (intervention/placebo arm) Psychostimulants 2.1/ 3.2% Analgesics 44.4/ 33.7% Antidepressants 28.6/ 27.8%  +
D